Conference Coverage

Apixaban prevails in study of 163,000 DOAC users

Publish date: April 16, 2018

 

REPORTING FROM ACC 2018

SOURCE: Deitelzweig SB. ACC 2018.

Pages

Recommended Reading

ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Internal Medicine
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Internal Medicine
Genotype did not significantly affect evacetrapib response
MDedge Internal Medicine
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Internal Medicine
MDedge Daily News: Improving wearable cardioverter defibrillators
MDedge Internal Medicine
MOMENTUM 3 HeartMate 3 LVAD ‘practice changing’
MDedge Internal Medicine
Barbershop intervention cuts blood pressure in black men
MDedge Internal Medicine
VIDEO: Patient vouchers prompt physicians to prescribe top antiplatelet drugs
MDedge Internal Medicine
VIDEO: PFO closure device 100% effective against future strokes
MDedge Internal Medicine
Cardiovascular risk in type 2 diabetes: Patients are often clueless
MDedge Internal Medicine

Related Articles